Validation of PET/MRI attenuation correction methodology in the study of brain tumours

BMC Medical Imaging

Table 1 Baseline demographic and patients’ characteristics

Characteristics of patients with ¹¹C-MET PET/MRI Patients n = 14 ¹¹C-MET PET/MRI scans n = 15 Lesions n = 18
	Neuropathological confirmation (Yes/No)	Pathological diagnosis	Metal implant and analysis (Yes/No)	Treatment (a/o C, GNR, R, S) (Yes/No)	Hotspot analysis overall group (Yes/No)	Hotspot analysis metal subgroup (Yes/No)	Hotspot analysis non-metal subgroup (Yes/No)
ID1	Yes	Melanoma metastasis	No	Yes	Yes	No	Yes
ID2	Yes	Astrocytoma WHO II	Yes	Yes	Yes	Yes	No
ID3	Yes	Anaplastic Astrocytoma WHO III	Yes	Yes	Yes	Yes	No
ID4	Yes	Lung cancer metastasis	No	Yes	Yes	No	Yes
ID5	Yes	Melanoma metastasis	Yes	Yes	Yes	Yes	No
ID6	Yes	BC metastasis	No	Yes	Yes	No	Yes
ID7	Yes	BC metastasis	No	Yes	Yes	No	Yes
ID8	Yes	BC metastasis	No	Yes	Yes	No	Yes
ID9	Yes	BC metastasis	No	Yes	Yes	No	Yes
ID10	Yes	Kidney cancer metastasis	No	Yes	Yes	No	Yes
ID11	Yes	OD WHO II-III	No	Yes	Yes	No	Yes
ID12	No	–	No	No	Yes	No	Yes
ID13	Yes	GBM WHO IV	Yes	Yes	Yes	Yes	No
ID14	Yes	Astrocytoma WHO II	Yes	Yes	No	No	No
ID15	Yes	OD WHO II	Yes	Yes	Yes	Yes	No
ID16 (same as in ID5)	Yes	Melanoma metastasis	Yes	Yes	Yes	Yes	No
ID17	No	–	No	No	Yes	No	Yes
ID18	Yes	Astrocytoma WHO II-III	Yes	Yes	Yes	Yes	No

BC breast cancer; C chemotherapy, GB glioblastoma, GNR gamma knife radiosurgery, R radiotherapy, OD oligodendroglioma, WHO World Health Organization

ISSN: 1471-2342